Search
Interferon alfa-n1
go.drugbank.com/drugs/DB00011ApprovedWithdrawnInterferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.
Categories: Interferon Type I, Cytochrome P-450 CYP1A2 InhibitorsProducts: WELLFERON INYECTABLE 5 MU/ML, WELLFERON INYECTABLE 10 MU/ML.Ropinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalRopinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547]. … In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: ROPINIROL-NEURAX 5 MG, ROPINIROL AL 5 MG FILMTABLPenciclovir
go.drugbank.com/drugs/DB00299ApprovedDisplaying low toxicity and good selectivity, penciclovir is a nucleoside analogue. … Penciclovir is a synthetic acyclic guanine derivative with antiviral activity used for the treatment of various herpes simplex virus (HSV) infections.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingSynonyms: 9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine, 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanineDoxorubicin
go.drugbank.com/drugs/DB00997ApprovedInvestigationalDoxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. … [A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic IndexSynonyms: (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside, (8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedionePamidronic acid
go.drugbank.com/drugs/DB00282ApprovedInvestigationalPamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid].[A203111] Pamidronic acid was first described in the literature in 1977. … [A203111] Pamidronic acid was granted FDA approval on 31 October 1991.[L13835]
Products: พามิซอล ชนิดฉีด 15 มก./5 มล., 30 มก./10 มล., Pamidronate Disodium Omega 6 mg/mlNirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[L44146] It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry process, and neutralizes several RSV A and B strains. … [A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies.
Categories: Respiratory Syncytial Virus Anti-F Protein Monoclonal AntibodySynonyms: Immunoglobulin g1-kappa, anti-(human respiratory syncytial virus fusion glycoprotein f0 (protein f))human monoclonal antibody.gamma.1 heavy chain (1-456) (human vh (homo sapiens ighv1-69*01(ighd)-ighj4, *01 (90.1%)) (8.8.19) (1-126) -homo sapiens ighg1*03Piperazine
go.drugbank.com/drugs/DB00592ApprovedVet approvedWithdrawnFirst used as a solvent for uric acid, the use of piperazine as an anthelmintic agent was first introduced in 1953. … Piperazine is an organic compound that consists of a six-membered ring containing two opposing nitrogen atoms.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: MEI-MEI WORM SYRUP 750 mg/5 ml, ASEPAR 100 MG 100 ML SURUPHydromorphone
go.drugbank.com/drugs/DB00327ApprovedIllicitInvestigationalStructurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. … [A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSynonyms: (-)-(5R)-4,5-Epoxy-3-hydroxy-9α-methylmorphinan-6-one, 6-Deoxy-7,8-dihydro-6-oxomorphineFusidic acid
go.drugbank.com/drugs/DB02703ApprovedInvestigationalAn antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. … It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.
Mixtures: Fusicutan 20 mg/g + 1 mg/g Creme, FUCICORT 20 MG/G + 1 MG/G KREM, 30 GCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsIsradipine
go.drugbank.com/drugs/DB00270ApprovedIt exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: DYNACIRC SRO 5 MG, DYNACIRC2.5 MG COMPRIMIDOS